BridgeMD
New treatment option for Alopecia Areata
Official title Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata
ClinicalTrials.gov ID: NCT06327581
What this study is testing
What is Lactic Acid?
Lactic Acid is an investigational medicine, given as a treatment applied to the skin, being studied as a potential treatment for alopecia areata.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Alopecia areata (AA) is an immunologically mediated disease characterized by non-scarring hair loss (Madni and Shapiro, 2000). AA is presented by rapid and complete hair loss in one or more round or oval patches, usually on the scalp, beard area, eyebrows, eyelashes, and less commonly, on other hairy areas of the body (Berker et al., 2010 and James et al., 2011) Alopecia areata is a T-cell-mediated autoimmune disease.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 16 and older
You may be able to join if
- Age ≥ 16 years old with localized patchy AA (up to 6 cm in diameter).
- Patients of both sexes
- Willing to participate in the study and to sign an informed consent.
You likely can't join if
- Patients who received systemic or topical treatment for AA in the last 3 months prior to the start of the study
- Patients with Alopecia totalis, universalis, ophiasis, or sisaipho
- Pregnant or lactating females
- Patients who had bleeding or coagulation disorders
- Immunocompromised patients
- Patients with known history of hypersensitivity to vit D
See the full eligibility criteria
- Age ≥ 16 years old with localized patchy AA (up to 6 cm in diameter).
- Patients of both sexes
- Willing to participate in the study and to sign an informed consent.
- Patients who received systemic or topical treatment for AA in the last 3 months prior to the start of the study
- Patients with Alopecia totalis, universalis, ophiasis, or sisaipho
- Pregnant or lactating females
- Patients who had bleeding or coagulation disorders
- Immunocompromised patients
- Patients with known history of hypersensitivity to vit D
- Patients taking vitamin D supplements in the last 6 months.
The study team makes the final eligibility decision.
Where it's taking place
- Zagazig, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 16 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zagazig, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.